Skip to content

Comparison of curative effect between surgery after neoadjuvant chemotherapy and radical gastrectomy plus pancreaticoduodenectomy in locally advanced gastric cancer

Comparison of curative effect between surgery after neoadjuvant chemotherapy and radical gastrectomy plus pancreaticoduodenectomy in locally advanced gastric cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200063959
Enrollment
Unknown
Registered
2022-09-22
Start date
2022-10-01
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally Advanced Gastric Cancer

Interventions

Radical gastrectomy and pancreatoduodenectomy group:None

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Gastric cancer was confirmed by pathology; 2. Preoperative imaging or intraoperative exploration diagnosed gastric cancer involving duodenum or head of pancreas; 3. Patients without distant metastasis and other tumors; 4. Complete clinical medical records and follow-up records of patients; 5. Directly receiving gastric cancer resection + pancreaticoduodenectomy was included in the GPD group, receiving 3 courses of neoadjuvant chemotherapy, then receiving gastric cancer resection or gastric cancer resection + pancreaticoduodenectomy was included in the NCS group. Clinical and pathological stages were classified according to the International Union Against Cancer TNM Classification of Malignancies (7th edition). The imaging diagnosis of locally advanced gastric cancer is based on Multidetector computed tomography (MDCT). The gastric cancer involves the duodenum, and the gastric tumor lesions or the fatty space between the perigastric lymph nodes and the head of the pancreas disappear.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
5-year overall survival;

Secondary

MeasureTime frame
short-term outcome;long-term outcome;

Countries

China

Contacts

Public ContactHe Nan

Wuhan Union Hospital

hero_nan@msn.com+86 27 85871851

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026